Swedish Orphan Biovitrum AB (publ) (0MTD.L)
LSE - LSE Delayed price. Currency in SEK
Add to watchlist
At close: 04:57PM GMT
| Previous close | 224.04 |
| Open | 220.00 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 212.20 - 220.30 |
| 52-week range | 212.20 - 220.30 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Has Swedish Orphan Biovitrum (BIOVF) Outpaced Other Medical Stocks This Year?
Here is how Swedish Orphan Biovitrum (BIOVF) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
- Business Wire
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
LAUSANNE, Switzerland, July 08, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan. The Marketing Authorization Application (MAA) for ZYNLONTA was validated by the European Medicines Agency (EMA) at the end of October 2021, and orphan d
© 2023 Yahoo. All rights reserved.
